The mitochondrial transporter SLC25A43 is frequently deleted and may influence cell proliferation in HER2-positive breast tumors
- Elisabet Tina†1, 2Email author,
- Breezy Malakkaran Lindqvist†2,
- Marike Gabrielson†2,
- Zelmina Lubovac3,
- Pia Wegman2 and
- Sten Wingren2
© Tina et al.; licensee BioMed Central Ltd. 2012
Received: 15 March 2012
Accepted: 31 July 2012
Published: 10 August 2012
Overexpression of the human epidermal growth factor receptor (HER) 2 is associated with poor prognosis and shortened survival in breast cancer patients. HER2 is a potent activator of several signaling pathways that support cell survival, proliferation and metabolism. In HER2-positive breast cancer there are most likely unexplored proteins that act directly or indirectly downstream of well established pathways and take part in tumor development and treatment response.
In order to identify novel copy number variations (CNVs) in HER2-positive breast cancer whole-genome single nucleotide polymorphism (SNP) arrays were used. A PCR-based loss of heterozygosis (LOH) assay was conducted to verify presence of deletion in HER2-positive breast cancer cases but also in HER2 negative breast cancers, cervical cancers and lung cancers. Screening for mutations was performed using single-strand conformation polymorphism (SSCP) followed by PCR sequencing. Protein expression was evaluated with immunohistochemistry (IHC).
A common deletion at chromosome Xq24 was found in 80% of the cases. This locus harbors the gene solute carrier (SLC) family 25A member 43 (SLC25A43) encoding for a mitochondrial transport protein. The LOH assay revealed presence of SLC25A43 deletion in HER2-positive (48%), HER2-negative (9%), cervical (42%) and lung (67%) cancers. HER2-positive tumors with negative or low SLC25A43 protein expression had significantly lower S-phase fraction compared to tumors with medium or high expression (P = 0.024).
We have found deletion in the SLC25A43 gene to be a common event in HER2-positive breast cancer as well as in other cancers. In addition, the SLC25A43 protein expression was shown to be related to S-phase fraction in HER2-positive breast cancer. Our results indicate a possible role of SLC25A43 in HER2-positive breast cancer and support the hypothesis of altered mitochondrial function in cancer.
KeywordsBreast cancer HER2 SLC25A43 S-phase
In approximately 20% of primary breast cancers, the tumor cells have acquired a capacity to increase their survival and proliferation by overexpressing the human epidermal growth factor receptor (HER) 2 [1, 2]. This overexpression of the HER2 protein is in the majority of cases caused by gene amplification . Patients diagnosed with a HER2-positive tumor have in general a higher risk for relapse, shorter time to disease progression, and poorer survival [1, 4, 5]. For over a decade, the recombinant humanized monoclonal antibody Trastuzumab has been used in clinic for treatment of HER2-positve breast cancer which has improved the outcome for these patients . However, acquired resistance to Trastuzumab is common among patients who initially respond, even when combined with chemotherapy [7–9]. For patients with tumor progression after treatment with Trastuzumab, lapatinib provides a new treatment option. Lapatinib is a small molecule that competitively binds to HER2 but also to the family member HER1, and thereby decreases activation of downstream signals .
Several signaling pathways associated with cell proliferation, cell growth, differentiation, survival and metabolism are activated by the HER-family . The Phoshatidylinositol-3-kinase (PI3K) pathway has been identified to have a significant role in HER2-positive breast cancer as well as in the development and progression of other cancers. Studies have shown that the PI3K pathway is frequently perturbed as a result of genetic alterations such as activating mutations in the PIK3CA gene , or mutation or deletion of the negative regulator phosphatase and tensin homologue (PTEN) [11, 12]. These genetic alterations can lead to constitutive activation of the PI3K pathway and thereby contribute to treatment failure [13, 14]. The HER2 network contributes to a plethora of cellular functions and there are most likely unexplored proteins acting directly or indirectly of downstream pathways affecting tumor development and treatment response.
The aim of the study was to identify novel copy number variations (CNVs), underlying development and progression of HER2-positive breast cancer, using whole-genome single nucleotide polymorphism arrays. The result revealed a common deletion of the gene encoding for the inner mitochondrial membrane transporter, solute carrier (SLC) family 25A member 43 (SLC25A43). Furthermore, the SLC25A43 protein was found to have a possible role in cell proliferation.
Patient characteristics and the SLC25A43 expression in the HER2-positive breast cancer cohort
No. of cases total in the cohort (%)
Mean values of total cases in the cohort
Mean age (years)
Mean size (mm)
Mean S-phase (%)
To further analyze presence of loss of heterozygosis in SLC25A43 in other malignancies, we included cohorts of HER2-negative breast cancers, cervical cancer and lung cancer. The cohort of HER2-negative, estrogen receptor (ER) positive breast cancers consisted of samples from 52 patients with a median age of 64 years. Cervical tumor samples were obtained from 65 patients (median age of 69 years). Finally, the cohort of lung cancers included 18 female patients (median age 63 years) diagnosed with adenocarcinoma.
Study layout of patient material
Number of patients
Lung cancer (♀)a
The research ethical committee at the Faculty of Health Science, Linköping, Sweden, approved this study with no request of an informed consent.
Isolation of DNA
DNA was isolated from approximately 10 mg of fresh frozen tissue and Buffy coat samples from female blood donor, using QIAamp® DNA Mini Kit or EZI DNA,QIAGEN® Tissue kit (both from QIAGEN Inc., Valencia, CA, USA) followed by purification using BioRobot EZI workstation (QIAGEN Inc.). DNA concentrations were quantified using NanoDrop® ND-1000 UV–vis Spectrophotometer (NanoDrop Technologies, Wilmington, DE, USA).
Whole-genome screening of CNVs was performed using Gene Chip® Mapping 250 K Assay Kit (Affymetrix, Inc Santa Clara, CA USA) according to manufacturer’s protocol. Briefly, 250 ng of DNA was digested with NspI restriction enzyme. The DNA fragments were then ligated with an adaptor and PCR amplified with general primers. The PCR product was purified, quantified and cleaved to shorter fragments, followed by labeling. Thereafter, the sample was hybridized to the array and then stained with a streptavidin-biotin solution. A Gene Chip Scanner 3000 7 G (Affymetrix) was used to scan the chip. To generate a segment report, which is a table where each row corresponds to a segment with copy number change that deviates from the expected normal, Genotyping Consol 3.1 (Affymetrix) was used. Array data from forty-six female individuals, available from the International Hap Map project, were used as controls for known CNV regions. To generate the segment report, three different criteria were applied by setting different values of the parameters provided by the application. One of the parameters is defined as the number of SNPs within the segment. By setting the value of this parameter to five, we introduce constraints to only identify segments with a minimum of five SNPs within the segment. The other parameter defined the size of the reported segment to a minimum size of 100 kbp. Finally, a parameter for CNV overlap was set to report all segments with up to 50% overlap with known CNV regions. For each segment, there is an indication of loss or gain, depending on whether the copy number change correspond to a decrease or increase from what is normally expected. Further bioinformatics analysis consisted of selecting the most frequent aberrations, present in a minimum of 10 tumors, and applying clustering tools to find common patterns of genetic changes among different patients .
Loss of heterozygosis assay
Loss of heterozygosis (LOH) analysis of the SLC25A43 gene was carried out by a PCR- restriction fragment length polymorphism (PCR-RFLP) based method. A polymorphic site, common among the European/Scandinavian population (SNP ID: rs217978), between exon 1 and 2 in the SLC25A43 gene was chosen for the analysis. PCR amplification was performed in a final reaction volume of 20 μl containing 25-50 ng of DNA, 1x TopTaq PCR buffer (1.5 mM MgCl2 (Qiagen) 0.2 mM of each dNTP, 0.025 U TopTaq DNA polymerase (Qiagen), 1x Q-solution™ (Qiagen) and 1 μM of primers flanking the SNP (5’-GCATTGGGAGAATGAGGAGT-3’, HEX5’-CTGTTGTGCTGCTTGCCTTC-3’ respectively). Amplification was carried out using the following conditions: initial denaturation (94°C for 3 min), followed by 35 cycles of denaturation (94°C for 30 sec), annealing (60°C for 30 sec) and extension (72°C for 60 sec, 5) ending with a final extension at 72°C for 10 min. The 101 bp PCR product was then cleaved at the polymorphic site using Acc1 (New England BioLabs Inc., Ipswich, MA, US) at 37°C for 8 hours followed by heat inactivation at 80°C for 20 minutes. The cleaved products were resolved by 3% agarose (w/v) gel electrophoresis and all samples heterozygous for rs.217978 were selected for capillary electrophoresis in an ABI Prism® 3130 Genetic Analyzer (Applied Biosystems, CA, USA). GeneMapper v 4.0 software was used for the analysis of the area under the peak which represents the amount of each allele. For each sample, an allelic ratio (AR) was calculated by dividing the peak area of allele 1 by the peak area of allele 2. To determine a reference interval (mean allelic ratio ± 1.96SD), 29 heterozygous female blood donors were used and tumor samples with an AR within the reference interval were defined to have retention of heterozygosis (ROH) while samples outside the range were considered to have LOH.
All exons of the SLC25A43 gene were screened in HER2-positve breast cancer samples using single-strand conformation polymorphism (SSCP). The primary PCR was performed in a total volume of 20 μl PCR containing 25-50 ng DNA, 1x TopTaq PCR buffer (1.5 mM MgCl2, 0.2 mM of each dNTP) (Qiagen), 0.025U TopTaq DNA polymerase (Qiagen), 1x Q-solution™ (Qiagen) and 1 μM of each primer (Additional file 1: Table S1). Amplification was carried out using the following conditions: initial denaturation (94°C for 3 min), followed by 30 cycles of denaturation (94°C for 30 sec), annealing (59 or 60°C for 30 sec) and extension (72°C for 60 sec) ending with a final extension (72°C for 10 min). These amplicons were then radiolabeled for single-strand conformation polymorphism (SSCP) in a secondary PCR, where 2 μl of the primary PCR product was amplified for 12 cycles in the presence of deoxyadenosine 5’-triphosphate, α-33P (Perkin Elmer, Boston, MA, USA). Fragments were run both on a non-denaturing 6% polyacrylamide gel at 6 W (3000 V, 300 mA) for 16-18 hours and on a MDE™ gel (Mutation Detection Enhancement, BMA products, Rockland, ME) for 8 hours at room temperature. The gel was dried and auto exposed to X-ray film (35 x 45 cm, Kodak BMS-1) in an exposure cassette using Trans Screen LE intensifier at -80°C for 1-2 days. The DNA fragments with mobility shifts were excised and preamplifier for sequencing by PCR. Cycle sequencing was performed using a BigDye® Terminator kit (Applied Biosystems, CA, USA) on 1 μl of clean PCR product (PCR-M ™ clean up system, VIOGENE, Sunnyvale, CA, USA) in a final volume of 10 μl containing 0.5x BigDye Terminator v1.1 Ready Reaction Mix, 0.5x BigDye Sequencing buffer, 0.16 μM of forward and reverse primers in a 2720 thermal cycler (Applied Biosystems, CA, USA) using following conditions; Initial denaturation (96°C for 60 sec), followed by 25 cycles of denaturation (96°C for 10 sec), annealing (50°C for 5 sec) and extension (60°C for 4 sec). The extension products were purified using an ethanol (95%) - Sodium acetate (3 M, pH 4.6) precipitation technique followed by capillary electrophoresis in an ABI Prism® 3130 Genetic Analyzer (Applied Biosystems CA, USA). A partial sequence of pGEM-3Zf (+) was used as control sequence. The results were analyzed using Sequencing Analysis v5.2 (CA, USA) and ChromasPro v1.34 developed by Technelysium Pty, Ltd.
To evaluate the association between LOH, IHC and ER/PgR-status or positive lymph nodes, χ 2 test were performed. Differences in age, tumor size or S-phase between LOH/ROH and IHC scoring were tested by Student’s T-test. Statistical significance was set at P < 0.05. SPSS 17.0 statistical software for Windows (SPSS Inc., Chicago, IL, USA) was used for all tests.
Deletion at Xq24 in HER2-positive breast cancer
Common loss of heterozygosity in SLC25A43
Loss of heterozygosity in different tumours
Type of cancer
Heterozygous patients (%)
Patients with LOH (%)
Lung cancer (♀)
The high frequency of LOH found in SLC25A43 indicated a possible role as a tumor suppressor gene. To investigate presence of a possible second genetic alteration in the SLC25A43 gene, ensuring complete inactivation of a tumor suppressor gene , we screened 29 HER2-positive breast tumors for mutations. However, we could not detect any mutation.
SLC25A43 expression varies in HER2-positive tumors
In this study, a common deletion of the SLC25A43 gene, located at Xq24, was revealed in HER2-positive breast cancer using whole-genome array. This novel finding indicates a possible role of SLC25A43 in HER2-positive breast cancer through an altered mitochondrial function.
CNVs have previously been reported at Xq in HER2-positive breast cancer [23, 24], supporting our finding. Deletions in X chromosome are also suggested to be associated with tumor progression, metastasis and poor prognosis in breast cancer . We further confirmed deletion in the SLC25A43 gene in a larger HER2-positive cohort using a PCR-based LOH assay. Deletion in SLC25A43 was also found to be present in other types of cancer in female patients, suggesting it to be a putative tumor suppressor gene. However, there were no mutations detected within the SLC25A43 gene in our cohort. Another possible mechanism for transcriptional silencing is increased methylation [26, 27], and recent findings show higher methylation in the CpG island of the SLC25A43 gene in breast cancer in the absence of gene deletion . Higher CpG island methylation was also associated with lower age at diagnosis in HER2-positive breast cancer  while deletion of SLC25A43 was found in tumors from patients with higher age at diagnosis. In females one of the two X chromosomes is randomly inactivated by DNA methylation , thus the need of two hits for complete inactivation of SLC25A43 depends on whether the deletion is localized on the active or inactive X chromosome. The limitation with the two methods used in the present study to determine occurrence of SLC25A43 deletion is that they do not discriminate between the active or inactive X chromosome.
When evaluating the protein expression with immunohistochemistry, results showed that SLC25A43 expression varied between negative to high among HER2-positive breast cancers and was not associated with ER status, lymph node metastasis or age at diagnosis. A possible explanation for the lack of association between LOH-status and protein expression could be the low number of cases available for comparison. It would therefore be of great interest to expand the cohort including cases with deletion in the SLC25A43 gene in the future. However, in our study the S-phase fraction was shown to be significantly lower in cases with negative or low SLC25A43 expression compared with medium or high expression of SLC25A43. It is currently not possible to explain the relation between SLC25A43 expression and S-phase fraction. Mitra et al have shown that the mitochondria also could have a role in cell cycle regulation  but the connection between SLC25A43 and cell proliferation has to be further elucidated.
The closest relative of SLC25A43 is the Coenzyme A (CoA) transporter SLC25A16, sharing 29% amino acid sequence similarity . The next closest relative, SLC25A42, has been shown to transport both CoA and ADP . Even though the function of SLC25A43 remains unexplored, alterations in the expression is likely to affect mitochondrial function. Mitochondrial dysfunction in cancer cells was first described by Otto Warburg in the 1920s where he demonstrated an increased glycolysis in the presence of oxygen (aerobic glycolysis) . Today, it is well established that mitochondrial dysfunction have an important role in tumor development and progression. Hanahan and Weinberg proposed that one of the hallmark capabilities in cancer cells is their enhanced resistance to mitochondrial apoptosis . Another hallmark is the sustained chronic proliferation found in cancer cells as a result of evading the strictly controlled production and release of growth factors as well as dysregulation of receptors and downstream signals .
Our findings of deletion in the SLC25A43 gene together with varied SLC25A43 protein expression in HER2-positive breast cancers supports the role of altered mitochondrial function as a hallmark of cancer.
To the best of our knowledge, this is the first report to demonstrate a common deletion in SLC25A43 in HER2-positive breast cancer as well as in other cancers, suggesting that it might be an important genetic event. The SLC25A43 protein expression was found to be related to S-phase fraction indicating a possible role of this mitochondrial protein in cell proliferation.
This study was supported by grants from Swedish Cancer Society, Nyckelfonden Örebro Sweden and Lion Cancer Foundation Sweden.
- Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987, 235 (4785): 177-182. 10.1126/science.3798106.View ArticlePubMedGoogle Scholar
- Prenzel N, Fischer OM, Streit S, Hart S, Ullrich A: The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer. 2001, 8 (1): 11-31. 10.1677/erc.0.0080011.View ArticlePubMedGoogle Scholar
- Owens MA, Horten BC, Da Silva MM: HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer. 2004, 5 (1): 63-69. 10.3816/CBC.2004.n.011.View ArticlePubMedGoogle Scholar
- Press MF, Bernstein L, Thomas PA, Meisner LF, Zhou JY, Ma Y, Hung G, Robinson RA, Harris C, El-Naggar A, et al: HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol. 1997, 15 (8): 2894-2904.PubMedGoogle Scholar
- Hartmann LC, Ingle JN, Wold LE, Farr GH, Grill JP, Su JQ, Maihle NJ, Krook JE, Witzig TE, Roche PC: Prognostic value of c-erbB2 overexpression in axillary lymph node positive breast cancer. Results from a randomized adjuvant treatment protocol. Cancer. 1994, 74 (11): 2956-2963. 10.1002/1097-0142(19941201)74:11<2956::AID-CNCR2820741111>3.0.CO;2-V.View ArticlePubMedGoogle Scholar
- Lantz E, Cunningham I, Higa GM: Targeting HER2 in breast cancer: overview of long-term experience. Int J Womens Health. 2010, 1: 155-171.PubMedPubMed CentralGoogle Scholar
- Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, et al: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001, 344 (11): 783-792. 10.1056/NEJM200103153441101.View ArticlePubMedGoogle Scholar
- Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, et al: 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet. 2007, 369 (9555): 29-36. 10.1016/S0140-6736(07)60028-2.View ArticlePubMedGoogle Scholar
- Esteva FJ, Valero V, Booser D, Guerra LT, Murray JL, Pusztai L, Cristofanilli M, Arun B, Esmaeli B, Fritsche HA, et al: Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol. 2002, 20 (7): 1800-1808. 10.1200/JCO.2002.07.058.View ArticlePubMedGoogle Scholar
- Chalhoub N, Baker SJ: PTEN and the PI3-kinase pathway in cancer. Annu Rev Pathol. 2009, 4: 127-150. 10.1146/annurev.pathol.4.110807.092311.View ArticlePubMedPubMed CentralGoogle Scholar
- Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI, Puc J, Miliaresis C, Rodgers L, McCombie R, et al: PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997, 275 (5308): 1943-1947. 10.1126/science.275.5308.1943.View ArticlePubMedGoogle Scholar
- Parsons R, Simpson L: PTEN and cancer. Methods Mol Biol. 2003, 222: 147-166.PubMedGoogle Scholar
- Wang L, Zhang Q, Zhang J, Sun S, Guo H, Jia Z, Wang B, Shao Z, Wang Z, Hu X: PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer. 2011, 11: 11-248. 10.1186/1471-2407-11-11.View ArticleGoogle Scholar
- Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA, Klos KS, Li P, Monia BP, Nguyen NT, et al: PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004, 6 (2): 117-127. 10.1016/j.ccr.2004.06.022.View ArticlePubMedGoogle Scholar
- Vindelov LL, Christensen IJ, Nissen NI: A detergent-trypsin method for the preparation of nuclei for flow cytometric DNA analysis. Cytometry. 1983, 3 (5): 323-327. 10.1002/cyto.990030503.View ArticlePubMedGoogle Scholar
- Caraux G, Pinloche S: PermutMatrix: a graphical environment to arrange gene expression profiles in optimal linear order. Bioinformatics. 2005, 21 (7): 1280-1281. 10.1093/bioinformatics/bti141.View ArticlePubMedGoogle Scholar
- Palmieri F: The mitochondrial transporter family (SLC25): physiological and pathological implications. Pflugers Arch. 2004, 447 (5): 689-709. 10.1007/s00424-003-1099-7.View ArticlePubMedGoogle Scholar
- Haitina T, Lindblom J, Renstrom T, Fredriksson R: Fourteen novel human members of mitochondrial solute carrier family 25 (SLC25) widely expressed in the central nervous system. Genomics. 2006, 88 (6): 779-790. 10.1016/j.ygeno.2006.06.016.View ArticlePubMedGoogle Scholar
- Schlessinger A, Matsson P, Shima JE, Pieper U, Yee SW, Kelly L, Apeltsin L, Stroud RM, Ferrin TE, Giacomini KM, et al: Comparison of human solute carriers. Protein Sci. 2010, 19 (3): 412-428.PubMedPubMed CentralGoogle Scholar
- Ellison JW, Li X, Francke U, Shapiro LJ: Rapid evolution of human pseudoautosomal genes and their mouse homologs. Mamm Genome. 1996, 7 (1): 25-30. 10.1007/s003359900007.View ArticlePubMedGoogle Scholar
- Robinson AJ, Overy C, Kunji ER: The mechanism of transport by mitochondrial carriers based on analysis of symmetry. Proc Natl Acad Sci U S A. 2008, 105 (46): 17766-17771. 10.1073/pnas.0809580105.View ArticlePubMedPubMed CentralGoogle Scholar
- Knudson AG: Mutation and cancer: statistical study of retinoblastoma. Proc Natl Acad Sci U S A. 1971, 68 (4): 820-823. 10.1073/pnas.68.4.820.View ArticlePubMedPubMed CentralGoogle Scholar
- Staaf J, Jonsson G, Ringner M, Baldetorp B, Borg A: Landscape of somatic allelic imbalances and copy number alterations in HER2-amplified breast cancer. Breast Cancer Res. 2011, 13 (6): R129-10.1186/bcr3075.View ArticlePubMedPubMed CentralGoogle Scholar
- Loo LW, Wang Y, Flynn EM, Lund MJ, Bowles EJ, Buist DS, Liff JM, Flagg EW, Coates RJ, Eley JW, et al: Genome-wide copy number alterations in subtypes of invasive breast cancers in young white and African American women. Breast Cancer Res Treat. 2011, 127 (1): 297-308. 10.1007/s10549-010-1297-x.View ArticlePubMedPubMed CentralGoogle Scholar
- Piao Z, Malkhosyan SR: Frequent loss Xq25 on the inactive X chromosome in primary breast carcinomas is associated with tumor grade and axillary lymph node metastasis. Genes Chromosomes Cancer. 2002, 33 (3): 262-269. 10.1002/gcc.10024.View ArticlePubMedGoogle Scholar
- Jones PA, Baylin SB: The epigenomics of cancer. Cell. 2007, 128 (4): 683-692. 10.1016/j.cell.2007.01.029.View ArticlePubMedPubMed CentralGoogle Scholar
- Portela A, Esteller M: Epigenetic modifications and human disease. Nat Biotechnol. 2010, 28 (10): 1057-1068. 10.1038/nbt.1685.View ArticlePubMedGoogle Scholar
- Lindqvist BM, Farkas SA, Wingren S, Nilsson TK: DNA methylation pattern of the SLC25A43 gene in breast cancer. Epigenetics. 2012, 7 (3): 300-306. 10.4161/epi.7.3.19064.View ArticlePubMedGoogle Scholar
- Brown CJ: Role of the X chromosome in cancer. J Natl Cancer Inst. 1996, 88 (8): 480-482. 10.1093/jnci/88.8.480.View ArticlePubMedGoogle Scholar
- Mitra K, Wunder C, Roysam B, Lin G, Lippincott-Schwartz J: A hyperfused mitochondrial state achieved at G1-S regulates cyclin E buildup and entry into S phase. Proc Natl Acad Sci U S A. 2009, 106 (29): 11960-11965. 10.1073/pnas.0904875106.View ArticlePubMedPubMed CentralGoogle Scholar
- Fiermonte G, Paradies E, Todisco S, Marobbio CM, Palmieri F: A novel member of solute carrier family 25 (SLC25A42) is a transporter of coenzyme A and adenosine 3',5'-diphosphate in human mitochondria. J Biol Chem. 2009, 284 (27): 18152-18159. 10.1074/jbc.M109.014118.View ArticlePubMedPubMed CentralGoogle Scholar
- Warburg O, Wind F, Negelein E: The Metabolism of Tumors in the Body. J Gen Physiol. 1927, 8 (6): 519-530. 10.1085/jgp.8.6.519.View ArticlePubMedPubMed CentralGoogle Scholar
- Hanahan D, Weinberg RA: Hallmarks of cancer: the next generation. Cell. 2011, 144 (5): 646-674. 10.1016/j.cell.2011.02.013.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/12/350/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.